Winlevi Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Winlevi Availability in 2026

Winlevi (Clascoterone) cream 1% remains the only FDA-approved topical androgen receptor inhibitor for acne vulgaris. Since its approval in August 2020, it has offered prescribers a novel mechanism of action for patients who haven't responded adequately to conventional topical therapies. However, real-world accessibility continues to present challenges that directly affect prescribing decisions and patient outcomes.

This briefing covers the current supply landscape, prescribing considerations, and actionable strategies to help your patients access Winlevi.

Timeline: Winlevi's Journey to Market

A brief overview of key milestones:

• August 2020: FDA approval of Winlevi (Clascoterone) cream 1% for acne vulgaris in patients 12 years and older. Designated as a first-in-class medication.
• 2020-2021: Initial market launch by Cassiopea. Early adoption primarily by dermatologists.
• 2022: Manufacturing transitioned under Sun Pharmaceutical Industries. Labeling updated July 2022.
• 2023-2025: Gradual growth in prescribing volume, but limited pharmacy stocking persisted due to brand-only status and cold storage requirements.
• 2026: No generic Clascoterone available. Not listed on FDA drug shortage database, but pharmacy-level availability remains inconsistent.

Prescribing Implications

Winlevi's unique mechanism — topical androgen receptor blockade — fills a gap in the acne treatment algorithm that no other topical agent addresses. Key clinical considerations:

Mechanism of action: Clascoterone competitively inhibits androgen receptors in sebocytes and hair follicles. In vitro, it demonstrates greater efficacy than Spironolactone and Enzalutamide at the androgen receptor. Importantly, systemic absorption is minimal, resulting in negligible systemic antiandrogenic effects.

Efficacy data: Two Phase III trials (N=1,421) demonstrated treatment success in 18-20% of Clascoterone-treated patients vs. 7-9% with vehicle, over 12 weeks. Acne symptom reduction was 8-18% greater than placebo.

Safety profile: Local skin reactions (erythema, scaling/dryness, pruritus) are the most common adverse effects and occur at rates similar to vehicle. HPA axis suppression was observed in 7% of tested subjects but was reversible within 4 weeks of discontinuation. Hyperkalemia was observed in 5% vs. 4% with placebo. Reproductive effects (polycystic ovaries, amenorrhea) have been noted in post-market surveillance.

Patient selection: Winlevi is particularly relevant for patients with hormonal acne patterns who prefer topical therapy, male patients who cannot use Spironolactone, and patients who have failed or cannot tolerate retinoids. It can be used as monotherapy or in combination with other topical agents.

Current Availability Picture

Despite adequate manufacturing supply from Sun Pharmaceutical, pharmacy-level availability remains problematic:

• Formal shortage status: Not listed on FDA or ASHP drug shortage databases as of early 2026
• Pharmacy stocking: Many chain pharmacies do not routinely stock Winlevi. Specialty and independent pharmacies near dermatology practices are more likely to carry it.
• Cold storage requirement: Winlevi must be refrigerated (2-8°C) prior to dispensing, which poses logistical challenges for some pharmacies
• Single manufacturer: No generic Clascoterone exists, limiting distribution breadth

Cost and Access Landscape

Cost remains a significant barrier to patient access:

• Average wholesale price: Approximately $846 per 60g tube
• Discount card pricing: ~$559 with programs like SingleCare
• Insurance coverage: Variable. Many commercial plans cover Winlevi but frequently require prior authorization and/or step therapy. Medicare Part D coverage varies by plan.
• Manufacturer programs: Sun Pharmaceutical may offer copay assistance. Direct patients to winlevi.com for current offerings.
• Patient assistance: For uninsured or underinsured patients, NeedyMeds and RxAssist databases may list applicable programs.

The lack of a generic option means that cost will likely remain a primary barrier until patent expiration.

Tools and Resources for Providers

Several resources can help you and your patients navigate Winlevi access:

Medfinder for Providers — A free platform that helps locate pharmacies with Winlevi in stock in real time. You can recommend this tool directly to patients or use it within your practice to identify the nearest stocked pharmacy before the patient leaves your office.

Prior authorization support: Having a standardized PA letter template that documents the patient's acne severity, previous treatments tried, and clinical rationale for Winlevi can expedite the approval process.

Samples: If available through your Sun Pharmaceutical representative, starter samples can bridge the gap while patients navigate insurance and pharmacy logistics.

Pharmacy partnerships: Establishing relationships with one or two pharmacies (especially independent or specialty pharmacies) that reliably stock Winlevi can streamline the fill process for your entire patient panel.

Looking Ahead

Several developments may affect Winlevi's landscape in the coming years:

• Generic timeline: No confirmed date for generic Clascoterone, but patent expiration timelines should be monitored
• Breezula (Clascoterone solution): Clascoterone is also under investigation for androgenetic alopecia under the name Breezula, which could increase overall manufacturing investment if approved
• Formulary evolution: As real-world evidence accumulates, more insurance plans may add Winlevi to preferred formulary tiers, reducing PA requirements

Final Thoughts

Winlevi fills a genuine unmet need in acne management, but access barriers remain significant in 2026. Proactive prescribing — including pharmacy selection guidance, PA preparation, and cost navigation — can meaningfully improve your patients' ability to access this medication.

For a patient-facing overview of availability issues, you can share our article: Winlevi shortage update for patients. For guidance on helping patients find the medication, see our provider's guide to helping patients find Winlevi.

Visit Medfinder for Providers to access real-time availability tools for your practice.